Literature DB >> 28595266

Melatonin protects against cisplatin-induced ovarian damage in mice via the MT1 receptor and antioxidant activity.

Ricássio S Barberino1, Vanúzia G Menezes1, Anita E A S Ribeiro2, Raimundo C Palheta2, Xuejun Jiang3, Johan E J Smitz4, Maria Helena T Matos1.   

Abstract

This study evaluated the receptor- and/or antioxidant stress-mediated mechanisms by which melatonin prevents the ovarian toxicity of cisplatin treatment. The expression of the MT1 receptor in mouse ovaries was investigated by immunohistochemistry. Pretreatment with melatonin (5, 10, or 20 mg/kg body weight, i.p.) before cisplatin (5 mg/kg body weight, i.p.) was administered to mice once daily for 3 days (phase I). The pharmacological modulation via melatonin type 1 and/or 2 receptors was analyzed by administration of receptor antagonists (luzindole: nonselective MT1/MT2 antagonist; 5 mg/kg body weight or 4-phenyl-2-propionamidotetralin: selective MT2 antagonist; 4 mg/kg body weight) once daily for 3 days, 15 min before the treatment with melatonin and cisplatin (phase II). Thereafter, the ovaries were harvested and used for histological (morphology and activation), immunohistochemical (PCNA, activated caspase-3 and bcl-2 expression), terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling, and fluorescence (reactive oxygen species [ROS], glutathione [GSH], and active mitochondria levels) analyses. The expression of the MT1 protein in mouse ovaries was documented. Pretreatment with 20 mg/kg melatonin before cisplatin administration preserved the normal follicular morphology and cell proliferation rate, reduced apoptosis, ROS production, mitochondrial damage and increased GSH expression, as compared to the cisplatin treatment alone. Additionally, administration of the nonselective MT1/MT2 receptor antagonist inhibited the melatonin ovarian protection from the cytotoxic effects of cisplatin. However, administration of a selective MT2 antagonist did not modify the protective effects observed at 20 mg/kg melatonin. In conclusion, pretreatment with 20 mg/kg melatonin effectively protected the ovaries against cisplatin-induced damage. Moreover, the MT1 receptor and melatonin antioxidant effects mediated this cytoprotective activity.
© The Authors 2017. Published by Oxford University Press on behalf of Society for the Study of Reproduction. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  female infertility; follicular development; hormone receptors; oocyte; ovary; premature ovarian failure

Mesh:

Substances:

Year:  2017        PMID: 28595266     DOI: 10.1093/biolre/iox053

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  21 in total

1.  Melatonin protects against chronic stress-induced oxidative meiotic defects in mice MII oocytes by regulating SIRT1.

Authors:  Ying Guo; Junyan Sun; Shixia Bu; Boning Li; Qiuwan Zhang; Qian Wang; Dongmei Lai
Journal:  Cell Cycle       Date:  2020-05-26       Impact factor: 4.534

Review 2.  The emerging link between cancer, metabolism, and circadian rhythms.

Authors:  Selma Masri; Paolo Sassone-Corsi
Journal:  Nat Med       Date:  2018-12-06       Impact factor: 53.440

3.  The Effect of Melatonin on OCT4 Expression and Granulosa Cell Growth in Female Mice.

Authors:  Baoqiang Fu; Dai Heng; Ningxin Li; Xiaoshu Ma; Qiaozhi Wang; Yanzhou Yang; Cheng Zhang
Journal:  Reprod Sci       Date:  2021-11-04       Impact factor: 2.924

4.  Continuous treatment with cisplatin induces the oocyte death of primordial follicles without activation.

Authors:  Maya Eldani; Yi Luan; Pauline C Xu; Tom Bargar; So-Youn Kim
Journal:  FASEB J       Date:  2020-08-23       Impact factor: 5.191

5.  Heat treatment and protective potentials of luteolin-7-O-glucoside against cisplatin genotoxic and cytotoxic effects.

Authors:  Mouna Maatouk; Besma Abed; Ines Bouhlel; Mounira Krifa; Rihab Khlifi; Irina Ioannou; Kamel Ghedira; Leila Chekir Ghedira
Journal:  Environ Sci Pollut Res Int       Date:  2020-02-05       Impact factor: 5.190

Review 6.  Mitochondria: Central Organelles for Melatonin's Antioxidant and Anti-Aging Actions.

Authors:  Russel J Reiter; Dun Xian Tan; Sergio Rosales-Corral; Annia Galano; Xin Jia Zhou; Bing Xu
Journal:  Molecules       Date:  2018-02-24       Impact factor: 4.411

Review 7.  Utilizing Melatonin to Alleviate Side Effects of Chemotherapy: A Potentially Good Partner for Treating Cancer with Ageing.

Authors:  Zhiqiang Ma; Liqun Xu; Dong Liu; Xiaoyan Zhang; Shouyin Di; Weimiao Li; Jiao Zhang; Russel J Reiter; Jing Han; Xiaofei Li; Xiaolong Yan
Journal:  Oxid Med Cell Longev       Date:  2020-05-21       Impact factor: 6.543

8.  ROS-Induced GATA4 and GATA6 Downregulation Inhibits StAR Expression in LPS-Treated Porcine Granulosa-Lutein Cells.

Authors:  Xiaolu Qu; Leyan Yan; Rihong Guo; Hui Li; Zhendan Shi
Journal:  Oxid Med Cell Longev       Date:  2019-04-22       Impact factor: 6.543

9.  Protective effects of melatonin against nicotine-induced disorder of mouse early folliculogenesis.

Authors:  Yu-Feng Wang; Xiao-Feng Sun; Ze-Li Han; Lan Li; Wei Ge; Yong Zhao; Massimo De Felici; Wei Shen; Shun-Feng Cheng
Journal:  Aging (Albany NY)       Date:  2018-03-28       Impact factor: 5.682

Review 10.  Melatonin: An Anti-Tumor Agent in Hormone-Dependent Cancers.

Authors:  Javier Menéndez-Menéndez; Carlos Martínez-Campa
Journal:  Int J Endocrinol       Date:  2018-10-02       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.